We are extremely proud on winning The Shay Rishoni Patient Impact Award. This award recognizes and rewards ALS/MND patients whose activities have made significant and outstanding contributions to ALS/MND research and drug discovery efforts. The award aims to acknowledge individuals living with ALS/MND whose active and entrepreneurial spirit has led them to pioneer large scale initiatives that have profoundly impacted and helped shape the ALS/MND research field.




We are proud to be mentioned in the latest issue of Health~Holland about our world wide fight against ALS. Read this interesting article and many more in the latest issue about Life Sciences & Health.




“One man can and will find a way, why not be that man”

It is with great sadness that we learned of the passing of GARMT VAN SOEST. Garmt had an endless ambition to find a cure for ALS. We are dedicated to continuing his mission.  We extend our deepest sympathies to his wife Iris, his daughter Zoë and his family. May memories of Garmt offer comfort and strength.




Treeway is door gemeente Tilburg en Citymarketing Tilburg uitgeroepen tot ‘Tilburgs bedrijf van de maand’. Deze bedrijven zijn ambassadeurs voor Tilburg als ondernemersstad. Het bedrijf sleept de prijs in de wacht voor haar grote betekenis in de ontwikkeling van een geneesmiddel tegen de dodelijke ziekte ALS.

Wethouder Erik de Ridder reikte de prijs uit tijdens een bezoek aan Treeway op 11 oktober. Erik de Ridder: “Dit bedrijf vervult een onmisbare rol in de zoektocht naar een medicijn tegen ALS. De slopende ziekte waaraan helaas nog steeds veel mensen overlijden. Hun vooruitstrevende en daadkrachtige onderzoeksmethode en hun missie om een geneesmiddel te ontwikkelen tegen ALS maakt dit bedrijf met recht Bedrijf van de Maand. Ik ben er enorm trots op dat een bedrijf als Treeway de gemeente Tilburg als uitvalsbasis heeft gekozen. En hoop dat het Treeway lukt om het zo gewenste geneesmiddel te vinden!”

Tilburg als uitvalsbasis
Ronald van der Geest, CDO en Hoofd Ontwikkeling: “Wij werken al jaren vanuit Tilburg en daar zijn we heel blij mee. Enerzijds is dat vanwege de aanwezigheid van 3D-PharmXchange, een bedrijf waar we veel mee samenwerken en dat hier gevestigd is. Anderzijds is Tilburg geografisch heel belangrijk; dichtbij België en centraal in Europa. We zijn een kennisbedrijf maar ook een internationaal bedrijf en werken wereldwijd samen met anderen partijen. Maar het denkwerk gebeurt hier, en dat gebeurt dus allemaal vanuit Tilburg.”

Mission Possible
Het werk vanuit Tilburg gaat verder dan alleen wetenschappelijk onderzoek. TW001 is het geneesmiddel dat op dit moment binnen Treeway het meest ver in zijn ontwikkeling is en is al in gezonde vrijwilligers en ALS-patiënten getest. De belangrijkste studie die nog moet plaatsvinden, is een grote studie bij ALS-patiënten waarbij het effect van TW001 op het verloop van de ziekte gedurende langere tijd wordt onderzocht. Inez de Greef, CEO Treeway: “Het ontwikkelen van een geneesmiddel duurt lang. Daarnaast zijn de kosten van ontwikkeling erg hoog, enkel voor de hierboven genoemde studie zijn er al miljoenen euro’s nodig. Deze stappen zijn echter noodzakelijk om uiteindelijk een goedkeuring te krijgen van het Europese geneesmiddelbureau, de voorwaarde om het geneesmiddel voor de kunnen schrijven aan ALS-patiënten. Een lange weg dus, maar zeker geen mission impossible.”

Klik hier voor de video:



Treeway Graduate Reward Winner


Last week, we officially awarded Steven Boeynaems for winning the Treeway Graduate Reward Program. Unfortunately, he was not able to collect his prize in person. Therefore, we welcomed Professor Ludo van den Bosch. He worked closely with Steven during his thesis and was happy to collect the prize and give a presentation about Steven’s research:


We wish Steven the best of luck in his future career and hope the prize will help him with his research.

Treeway Graduate Reward Program Winner!

Today is World ALS Day and we are happy to announce this year’s winner of the Treeway Graduate Reward Program:

Congratulations Steven Boeynaems!

Steven has been interested in ALS for quite some time and he wrote his thesis about his research regarding the link between mechanisms in C9orf72 and ALS and FTLD. This summer he will join the Gitler lab at Stanford to work further on the mechanisms underlying the onset of the disease. The grant that Steven won with the Treeway Graduate Reward Program will be used to fund experiments for his research.

We wish Steven the best of luck in his career and we truly believe that his work will be of great importance for the ALS community.

Radicava® approved for treatment of ALS in United States

On May 5, 2017, the Food and Drug Administration (FDA) approved Radicava® to treat patients with amyotrophic lateral sclerosis (ALS) in the United States. The active ingredient of Radicava® is edaravone. Edaravone was originally developed by the Japanese pharmaceutical company Mitsubishi Tanabe for the treatment of acute ischaemic stroke. Subsequently, clinical trials in ALS patients demonstrated that the progression of ALS with edaravone could be delayed. These trials were all carried out in Japan. Since 2015 edaravone is on the market for the treatment of ALS in Japan under the brand name Radicut®. Hereafter, FDA approval was requested for the US market which has now been obtained.

Radicava® is administered directly into a vein by means of a 60-minute infusion. Dosing is done in repeated treatment cycles of 28-days. Infusions are given in 10 of 14 days in the first two weeks, followed by a 14 days drug-free period ‘(drug holiday’). Radicava® may be administered in a hospital or by a health care professional at home.

Treeway is pleased with the approval of Radicava® in the United States. We feel supported by the recognition of the efficacy of edaravone by the FDA. The approval of Radicava® does not interfere with Treeway’s plans for TW001, the treatment we have in development for the oral administration of edaravone.

First ALS Patients Connected Meeting was a success!

In January, the first successful mutual meeting between biotech company Treeway and patient organization ‘ALS Patients Connected’ was organized. Treeway is initiated ‘by patients and for patients’ and this meeting – where we entered into a conversation with one another – is an important aspect.  We introduced ourselves and explained our way of working. Although there has not been found a solution to cure ALS yet, we are moving forward in our search for a therapy. One of the things that were highlighted during this meeting is the importance of collecting and sharing ‘real life data’ in order to obtain even better results for the continual development of a therapy. ALS Patients Connected can play an important role here. This meeting is a good example of how we can work closely together and to improve and speed up the research and development of a therapy. For more information about APC:


Post-doc position for 3 years

In collaboration with the University Medical Center Utrecht, Treeway is looking for an enthousiastic post-doc who will be supporting extensive bio-informatic analysis of the genetic data obtained within Project MinE. Project MinE ( is the world’s largest research initiative devoted to discovering genetic causes, risk factors and disease pathways of ALS by collection of whole genome DNA sequences from 15,000 ALS patients and 7,500 healthy control persons. Integration of these genetic data with publically available biological pathway databases, drug databases and literature results, new biological pathways involved in ALS, new drug targets for ALS and repurposing of existing drugs for ALS might be identified and could as such lead to a new drug therapy for ALS.

Please, click the following link for more information and to apply for this job opportunity:

About ALS

Amyotrophic Lateral Sclerosis (ALS) is a devastating progressive, neurodegenerative disease that causes death of motor neuron populations. The loss of motor neurons leads to muscle weakness, difficulty in swallowing, speech and eventual paralysis. Average disease duration is 2-5 years. It is an orphan disease with an incidence of 2 of 100.000, and a life chance of 1:300. Its occurrence is mostly between the age of 40-60 years, although also at other ages ALS is diagnosed. Of all diagnoses, 10% is familial and 90% is ‘sporadic’. For the familial form, different genes have been identified, although the exact mechanism of the cause and the progress of ALS is unknown. Currently, there is only one approved ALS drug therapy, riluzole, but this is prolonging life by only 3 months. Therefore, there is an urgent need for improved drug therapy.

About Treeway

Treeway is a biotech company founded by ALS patients, and our mission is to change the devastating disease Amyotrophic Lateral Sclerosis (ALS) into a chronic disease. Treeway Therapeutics aims to do rational target validation and drug development with a patient-driven fast-track focus and we have established high-potential research and development focus areas up to clinical phase II/III program leading to orphan drug status and early access.

Inez de Greef and Ronald van der Geest were invited to the Drug Discovery and Development Workshop in Florida from 7 to 9 October, organized by the ALS Association. The progress of the second product of Treeway, TW002, will be presented. TW002 is a gene therapy whereby GDNF is delivered with the viral vector of AAV5.